Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosign Technologies Inc BITKF

Biosign Technologies Inc is a Canada based company engaged in the development and selling of cloud-based medical and healthcare software products. Its solutions have applications in clinic management, home care operations, health monitoring and virtual care management. The group derives its revenue from monthly recurring fees, one-time setup charges, training, professional services and the sale of hardware. The software is delivered through the cloud from the company's hosting facilities.


GREY:BITKF - Post by User

Post by bluepen1on Nov 13, 2013 11:07am
116 Views
Post# 21901458

mHealth Technology study using Biosign's Healthanywhere app

mHealth Technology study using Biosign's Healthanywhere appInteresting article here:

https://www.fiercemobilehealthcare.com/story/mhealth-improves-risk-profile-cardiovascular-disease-type-2-diabetes-patien/2013-11-08

mHealth improves risk profile in cardiovascular disease, type 2 diabetes patients

November 8, 2013 | By Greg Slabodkin

A provisional article published in the peer-reviewed journal BMC Public Health suggests that mHealth technology supporting exercise prescription interventions can be effective.

The findings are based on a Canadian study of 149 adults with at least two metabolic syndrome risk factors, one group using the intervention and one control group.

"Mobile health technologies have proved to be a beneficial tool to achieve blood pressure and blood glucose control in patients with diabetes," argue the authors, who are currently completing their analyses‎ and will be submitting their data for publication in the next few weeks. "These technologies may address the limited access to health interventions in rural and remote regions. However, the potential as a tool to support exercise-based prevention activities is not well understood."

The study was undertaken to "investigate the effects of a tailored exercise prescription alone or supported by mobile health technologies to improve metabolic syndrome and related cardiometabolic risk factors in rural community-dwelling adults at risk for cardiovascular disease and type 2 diabetes," states the article. The authors hypothesized that the primary outcome, systolic blood pressure, and secondary outcomes would be improved in both groups, but to a greater extent in the mobile health intervention group at 12 weeks and that these changes would be better maintained at 24 and 52 weeks in the intervention group with mobile health support, compared with the active control group.

The results of the study "will contribute to the current literature by investigating the utility of mobile health technology support for exercise prescription interventions to improve cardiometabolic risk status and maintain improvements over time, particularly in rural communities," concludes the provisional article, which serves as a protocol paper.

Study participants were recruited from rural communities in Ontario, Canada. Participants were randomized to either: an intervention group receiving an exercise prescription and devices for monitoring of risk factors with a smartphone data portal equipped with a mobile health application; or an active control group receiving only an exercise prescription.

In addition to the exercise prescription, the intervention group received a mobile health technology kit for self-monitoring of biometrics and physical activity. The kit included a smartphone (Blackberry Curve 8300 or 8530) equipped with Healthanywhere health monitoring app (Biosign Technologies), a Bluetooth-enabled blood pressure monitor (A & D Medical), a glucometer (Lifescan One Touch Ultra2) with Bluetooth adapter (Polymap Wireless) and a pedometer (Omron).

Nevertheless, a recent study in the Journal of Medical Internet Research found that although mobile health interventions are effective in promoting physical activity, their degree of validity reported in studies is unclear.

Using the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework, the review revealed a recent increase in studies conducted to determine the effectiveness of mHealth interventions for the promotion of physical activity. Yet, quantity, not quality, seems to prevail, the authors argued.

To learn more:
- read the article in BMC Public Health

<< Previous
Bullboard Posts
Next >>